CD160 and non-small cell lung carcinoma: Then, prognostic analysis of 31 SLC6A8-associated immunomodulators in NSCLC indicated BLTA, CD160, CD40LG, and TNFRSF13C as low-risk factors and NT5E as high-risk factors (Figure 6B).